Download PDF
Pharmacopsychiatry 2021; 54(05): 246-247
DOI: 10.1055/a-1481-9058
Letter to the Editor

Failing Memory in Nonaffective Psychosis and Prolactin Response to 12.5 µg i.v. TRH

Johan Spoov
1   Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland
,
Per-Erik Bredbacka
2   Päijät-Häme Central Hospital, Lahti, Finland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Dear Editor

The increase in plasma prolactin at 15 min following administration of 12.5 µg TRH i. v. (∆prol) was introduced in Pharmacopsychiatry as an inverse estimate of tuberoinfundibular dopamine (TIDA) activity [1]. We used the unpublished data set in 20 participants with nonaffective psychosis from our 1991 study utilizing ∆prol [2] and here report new results with its association with memory.



Publication History

Received: 12 February 2021

Accepted: 12 April 2021

Article published online:
12 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Spoov J. Submaximal plasma prolactin response to TRH and dopamine activity in man. Pharmacopsychiatry 1985; 18: 330-332
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Spoov J, Bredbacka P-E, Appelberg B. et al. Prolactin response to submaximal stimulation by TRH in nonaffective psychoses. Biol Psychiatry 1991; 29: 204-210
    CrossrefPubMedGoogle Scholar
  • 3 Hill-Samli M, MacLeod RM. Interaction of thyrotropin-releasing hormone and dopamine on the release of prolactin from the rat anterior pituitary in vitro. Endocrinology 1974; 95: 1189-1192
    CrossrefPubMedGoogle Scholar
  • 4 Spoov J, Karonen S-L. Urinary HVA reflects central dopamine activity in man. New Trends Exp Clin Psychiatry 1987; 3: 93-99
    PubMedGoogle Scholar
  • 5 Spoov J, Bredbacka PE, Stenman UH. Separation of hallucinations from other positive symptoms by prolactin response to 12.5 μg i. v. TRH (mini-TRH test). Schizophr Res 2020; 220: 287-288
    CrossrefPubMedGoogle Scholar
  • 6 Gary KA, Sevarino KA, Yarbrough GG. et al. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for the TRH-based therapeutics. J Pharmacol Exp Ther 2003; 305: 410-416
    CrossrefPubMedGoogle Scholar
  • 7 Engber TM, Manaker S, Kreider MS, Winokur A. Intraventricular 6-hydroxydopamine increases thyrotropin-releasing hormone (TRH) content in regions of rat brain. Regul Pept 1985; 12: 51-57
    CrossrefPubMedGoogle Scholar
  • 8 Slifstein M, van de Giessen E, Van Snellenberg J. et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA psychiatry 2015; 72: 316-324
    CrossrefPubMedGoogle Scholar
  • 9 Fennig S, Mottes A, Ricter-Levin G. et al. Everyday memory and laboratory memory tests: general function predictors in schizophrenia and remitted depression. J Nerv Ment Dis 2002; 190: 677-682
    CrossrefPubMedGoogle Scholar